ArticleInfection and drug resistance2025
COMMD1 Regulates Osteoclast Differentiation in Talaromyces marneffei-Induced Osteomyelitis via the NF-κB Pathway.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study investigated the role of copper metabolism MURR1 domain-containing 1 (COMMD1) in Talaromyces marneffei (TM)-induced osteomyelitis (OM) and its regulation of osteoclast differentiation via the NF-κB pathway. Methods: A murine TM infection model was used to assess bone destruction and osteoclast activity via micro-CT, histological analysis, biomechanical testing, qPCR, and Western blot. RNA sequencing was performed to analyze differentially expressed genes. Functional validation was conducted using COMMD1 conditional knockout (cKO) mice and bone marrow-derived monocytes macrophages (BMMs). The NF-κB inhibitor JSH-23 was used to verify pathway dependency. Results: TM infection significantly upregulated inflammatory cytokines (IL-10, IL-17, TNF-α) and induced severe bone structural damage, characterized by trabecular thinning and reduced mechanical strength. These changes were accompanied by increased osteoclast numbers and elevated expression of osteoclast differentiation-related genes (TRAP, NFATc1, Ctsk, FOS). RNA sequencing revealed downregulation of COMMD1 and activation of the NF-κB pathway in TM-infected mice. COMMD1 deficiency exacerbated bone destruction and osteoclast differentiation, while COMMD1 overexpression suppressed these effects. Mechanistic studies showed that COMMD1 deletion increased P65 phosphorylation and decreased IκBα expression, effects that were reversed by JSH-23 treatment. Conclusion: COMMD1 protects against TM-induced OM by inhibiting the NF-κB pathway, suggesting it as a potential therapeutic target for bone infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.